Importance of prostatic sonography in the evaluation of conservative therapy of prostatic hyperplasia.
Drug therapy using an alpha-reductase inhibitor is being conducted in 23 patients with benign prostatic hyperplasia (BPH), hopefully resulting in a decrease in prostatic volume. Suprapubic ultrasonography determination of prostatic size has proven to be a reliable parameter of the disease course. In 142 evaluated ultrasonic measurements, a maximum deviation of +/- 7% for the diameter and +/- 13% for the volume was established. Therefore a change in volume after drug therapy of BPH can only be considered significant if a decrease in volume is 15% or more.
Department of Urology, University Hospital of Zürich, Switzerland.
J L
JL
Fehr
H
H
Knönagel
D058891:5-alpha Reductase Inhibitors; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy; D014463:Ultrasonography
D058891:5-alpha Reductase Inhibitors